TEGAFUR

/static/temp/default.svg

Search structure


Synonyms	Atillon BMS-200604 Citofur Coparogin Exonal FT-207 Fental Franrose Ftorafur Fulaid Fulfeel Furafluor Furofutran Futraful J356.722B Lamar Lifril MJF-12264 NSC-148958 Neberk Nitobanil Sinoflurol Sunfural Tefsiel c Tegafur Tegafur-uracil Uftoral Youfuding
Status
Molecule Category	UNKNOWN
ATC	L01BC03
UNII	1548R74NSZ
EPA CompTox	DTXSID8021305


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	WFWLQNSHRPWKFK-UHFFFAOYSA-N
Smiles	O=c1[nH]c(=O)n(C2CCCO2)cc1F
InChI	InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C8H9FN2O3
Molecular Weight	200.17
AlogP	-0.02
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	1.0
Polar Surface Area	64.09
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	14.0

Bioactivity

Mechanism of Action	Action	Reference
DNA inhibitor	INHIBITOR	EMA


Protein: Thymidylate synthase Description: Thymidylate synthase Organism : Homo sapiens P04818 ENSG00000176890

Assay Description	Organism	Bioactivity	Reference
Evaluated in vitro for the Cytotoxic activity in the L1210 cell culture screen at 1 uM Maximum cell kill in a 72-h period	Mus musculus	17.2 %
Evaluated in vitro for the Cytotoxic activity in the L1210 cell culture screen at 10 uM Maximum cell kill in a 72-h period	Mus musculus	67.5 %
Evaluated in vitro for the Cytotoxic activity in the L1210 cell culture screen at 100 uM Maximum cell kill in a 72-h period r	Mus musculus	81.8 %
Cytotoxicity against human Ec9706 cells at 200 uM after 48 hrs by MTT assay	Homo sapiens	7.8 %
Cytotoxicity against human Ec9706 cells at 400 uM after 48 hrs by MTT assay	Homo sapiens	17.4 %
Cytotoxicity against human A549 cells at 100 uM after 48 hrs by MTT assay	Homo sapiens	12.7 %
Cytotoxicity against human A549 cells at 200 uM after 48 hrs by MTT assay	Homo sapiens	15.2 %
Cytotoxicity against human A549 cells at 400 uM after 48 hrs by MTT assay	Homo sapiens	17.8 %
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)	Staphylococcus aureus subsp. aureus	17.75 %
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)	Escherichia coli	8.41 %
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)	Klebsiella pneumoniae	13.49 %
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)	Pseudomonas aeruginosa	21.04 %
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600	Acinetobacter baumannii	30.31 %
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630	Candida albicans	3.66 %
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)	Cryptococcus neoformans	-3.75 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	21.54 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.05 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.05 %

Cross References

Resources	Reference
ChEBI	32188
ChEMBL	CHEMBL20883
DrugBank	DB09256
DrugCentral	4398
FDA SRS	1548R74NSZ
Guide to Pharmacology	10513
KEGG	C12673
PubChem	5386
SureChEMBL	SCHEMBL4552

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).